tradingkey.logo
tradingkey.logo
Search

Fulgent Genetics Inc

FLGT
Add to Watchlist
20.850USD
+0.030+0.14%
Close 07/02, 13:00ETQuotes delayed by 15 min
601.54MMarket Cap
LossP/E TTM

More Details of Fulgent Genetics Inc Company

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fulgent Genetics Inc Info

Ticker SymbolFLGT
Company nameFulgent Genetics Inc
IPO dateSep 28, 2016
CEOHsieh (Ming)
Number of employees1313
Security typeOrdinary Share
Fiscal year-endSep 28
Address4399 Santa Anita Ave
CityEL MONTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91731
Phone16263500537
Websitehttps://www.fulgentgenetics.com/
Ticker SymbolFLGT
IPO dateSep 28, 2016
CEOHsieh (Ming)

Company Executives of Fulgent Genetics Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.87M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
926.77K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
286.01K
-0.73%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
282.94K
-0.76%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
18.61K
+59.73%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
16.33K
+34.04%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
15.54K
-16.55%
Ms. Melanie Solomon
Ms. Melanie Solomon
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.87M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
926.77K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
286.01K
-0.73%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
282.94K
-0.76%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
18.61K
+59.73%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
16.33K
+34.04%

FAQs

Who are the top five shareholders of Fulgent Genetics Inc?

The top five shareholders of Fulgent Genetics Inc are: Mr. Ming Hsieh

How many institutions hold shares of Fulgent Genetics Inc (FLGT)?

As of 2026Q1, 430 institutions hold shares of Fulgent Genetics Inc, with a combined market value of approximately 18.21M, accounting for 64.11% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1416587.00.

What is the biggest source of revenue for Fulgent Genetics Inc?

In 2026Q1, the Institutional business generated the highest revenue for Fulgent Genetics Inc, amounting to 184.60M and accounting for 57.21% of total revenue.